British journal of cancer · 1995

VAD chemotherapy as remission induction for multiple myeloma.

Название и аннотация: Перевод в очереди

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Anderson H, Scarffe JH, Ranson M, Young R, Wieringa GS, Morgenstern GR, Fitzsimmons L, Ryder D

Аннотация

A total of 142 patients with multiple myeloma received VAD as remission induction therapy. Seventy-five were previously untreated and 67 had relapsed (31) or refractory disease (36). Vincristine (total dose 1.6 mg) was infused with doxorubicin 36 mg m-2 by continuous ambulatory pump over 4 days. In addition, oral dexamethasone 40 mg day-1 was given for 4 days. Intermittent dexamethasone was only given to 19 patients. Courses were repeated every 21 days. The overall response rate was 84% [27% complete response (CR)] in previously untreated patients and 61% (3% CR) in patients with relapsed and refractory disease. The median survival was 36 months for untreated patients and 10 months for those who had received prior therapy. VAD was well tolerated; however, despite prophylaxis, 54% patients received antibiotics at some time during therapy and 37% had dyspepsia. Twenty-three patients subsequently received a transplant (eight allografts, eight marrow autografts and seven peripheral blood stem cell transplants). Eight have died-four in the allogeneic group and four in the autologous group. The overall median survival of transplanted patients has not yet been reached. VAD is an effective, out-patient therapy for inducing remission in multiple myeloma. Post-remission therapy needs to be optimised, but it is likely that the needs of previously untreated patients may be different from those with relapsed and refractory disease.

Перевод полного текста: Перевод в очереди

Читать найденный полный текст

https://creativecommons.org/licenses/by/4.0/ This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/ .

Alexanian R. Barlogie B. Dixon D. High-dose glucocorticoid treatment of resistant myeloma. 105 1 7 1986 8 11 Ann Intern Med 3717812 10.7326/0003-4819-105-1-8

Anderson H. Scarffe J. H. Lambert M. Smith D. B. Chan C. C. Chadwick G. McMahon A. Chang J. Crowther D. Swindell R. VAD chemotherapy--toxicity and efficacy--in patients with multiple myeloma and other lymphoid malignancies. 5 3 Jul-Sep 1987 213 222 Hematol Oncol 3115884 10.1002/hon.2900050308

Attal M. Huguet F. Schlaifer D. Payen C. Laroche M. Fournie B. Mazieres B. Pris J. Laurent G. Intensive combined therapy for previously untreated aggressive myeloma. 79 5 1 3 1992 1130 1136 Blood 1536941

Barlogie B. Smith L. Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. 310 21 24 5 1984 1353 1356 N Engl J Med 6546971 10.1056/NEJM198405243102104

Browman G. P. Belch A. Skillings J. Wilson K. Bergsagel D. Johnston D. Pater J. L. Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group. 82 3 11 1992 555 559 Br J Haematol 1486035 10.1111/j.1365-2141.1992.tb06466.x

Durie B. G. Salmon S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. 36 3 9 1975 842 854 Cancer 1182674 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u

Gahrton G. Tura S. Ljungman P. Belanger C. Brandt L. Cavo M. Facon T. Granena A. Gore M. Gratwohl A. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. 325 18 31 10 1991 1267 1273 N Engl J Med 1922221 10.1056/NEJM199110313251802

Gore M. E. Selby P. J. Viner C. Clark P. I. Meldrum M. Millar B. Bell J. Maitland J. A. Milan S. Judson I. R. Intensive treatment of multiple myeloma and criteria for complete remission. 2 8668 14 10 1989 879 882 Lancet 2571812 10.1016/s0140-6736(89)91548-1

Gregory W. M. Richards M. A. Malpas J. S. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. 10 2 2 1992 334 342 J Clin Oncol 1531068 10.1200/JCO.1992.10.2.334

Jonsson B. Nilsson K. Nygren P. Larsson R. SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma. 3 6 12 1992 641 646 Anticancer Drugs 1363199 10.1097/00001813-199212000-00013

Klein B. Zhang X. G. Jourdan M. Boiron J. M. Portier M. Lu Z. Y. Wijdenes J. Brochier J. Bataille R. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. 1 4 Oct-Nov 1990 193 201 Eur Cytokine Netw 2104241

MacLennan I. C. Chapman C. Dunn J. Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. 339 8787 25 1 1992 200 205 Lancet 1346171 10.1016/0140-6736(92)90004-m

Mandelli F. Avvisati G. Amadori S. Boccadoro M. Gernone A. Lauta V. M. Marmont F. Petrucci M. T. Tribalto M. Vegna M. L. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. 322 20 17 5 1990 1430 1434 N Engl J Med 2184356 10.1056/NEJM199005173222005

Miller A. B. Hoogstraten B. Staquet M. Winkler A. Reporting results of cancer treatment. 47 1 1 1 1981 207 214 Cancer 7459811 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6

Palumbo A. Boccadoro M. Garino L. A. Gallone G. Frieri R. Pileri A. Multiple myeloma: intensified maintenance therapy with recombinant interferon-alpha-2b plus glucocorticoids. 49 2 8 1992 93 97 Eur J Haematol 1397246 10.1111/j.1600-0609.1992.tb00037.x

Pettengell R. Morgenstern G. R. Woll P. J. Chang J. Rowlands M. Young R. Radford J. A. Scarffe J. H. Testa N. G. Crowther D. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. 82 12 15 12 1993 3770 3777 Blood 7505124

Samson D. Gaminara E. Newland A. Van de Pette J. Kearney J. McCarthy D. Joyner M. Aston L. Mitchell T. Hamon M. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. 2 8668 14 10 1989 882 885 Lancet 2571813 10.1016/s0140-6736(89)91549-3

San Miguel J. F. Moro M. Bladé J. Guerras L. Hernandez J. Jimenez-Galindo R. Ortega F. Gonzalez M. Combination of interferon and dexamethasone in refractory multiple myeloma. 8 4 Jul-Aug 1990 185 189 Hematol Oncol 2210687 10.1002/hon.2900080403

Selby P. J. McElwain T. J. Nandi A. C. Perren T. J. Powles R. L. Tillyer C. R. Osborne R. J. Slevin M. L. Malpas J. S. Multiple myeloma treated with high dose intravenous melphalan. 66 1 5 1987 55 62 Br J Haematol 3593657 10.1111/j.1365-2141.1987.tb06890.x

Ventura G. J. Barlogie B. Hester J. P. Yau J. C. LeMaistre C. F. Wallerstein R. O. Spinolo J. A. Dicke K. A. Horwitz L. H. Alexanian R. High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma. 5 4 4 1990 265 268 Bone Marrow Transplant 1970939

Woodruff R. Treatment of multiple myeloma. 8 4 12 1981 225 270 Cancer Treat Rev 7039824 10.1016/s0305-7372(81)80010-2

VAD chemotherapy as remission induction for multiple myeloma.

Ошибки и ограничения

Аннотация